Sign in
Not yet taking people in United StatesNo phase

Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer

Key facts

Who runs it
Wake Forest University Health Sciences
Where
Winston-Salem, United StatesSee the site
Trial code
Status
Not yet recruiting
People taking part
5,000 people, planned
Starts
Dec 2026
Expected to end
Dec 2032
Type of study
Observational
Treatments tested
  • The central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Age ≥18 years
  • Diagnosis of prostate cancer documented in the institutional medical record. Prostate adenocarcinoma will constitute the principal analytic population, while other prostate cancer histology's may be retained for descriptive background analyses when clinically relevant
  • Evaluation, diagnosis, treatment, or follow-up within or beyond Advocate Health Wake Forest Baptist / Wake Forest University School of Medicine and availability of sufficient clinical information for at least one study objective
  • For the prospective component, first ascertainment after protocol activation will be conducted through routine clinical records or institutional clinical data systems
  • For the historical background component, available institutional records predating protocol activation will be used to characterize prostate cancer presentation, management, and outcomes

Who cannot take part

  • Insufficient clinical information to establish the relevant diagnosis, treatment, or outcome for a proposed analysis
  • Records that cannot be used under applicable institutional privacy, data-governance, or IRB requirements

Where in United States

  • Wake Forest University Health SciencesWinston-Salem, United StatesContact: Sachin Vyas, MS, PhDNot yet recruiting

About the trial

What the trial wants to find out

Management of prostate cancer increasingly integrates conventional clinicopathologic risk factors with multiparametric magnetic resonance imaging (mpMRI), targeted and systematic biopsy, molecular imaging, and selected tissue-based genomic biomarkers. Contemporary guidelines emphasize risk-adapted shared decision-making and allow selective use of tissue-based genomic biomarkers when additional risk stratification may alter management discussions.

The group in the trial

  • Patients been diagnosed with the prostate cancer

    To determine how clinically obtained tumor genomic and transcriptomic features, phenotype, real-world treatment selection, and longitudinal oncologic outcomes

    Treatment: The central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ICEBERG-PC: Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer: A Single-Site AmbidirectionalObservational Outcomes Cohort
Record updated
16 November 2026